SLC5A2 and type 2 diabetes mellitus: This model is highly responsive to most major therapies used in the treatment of T2D, including the first-line therapy metformin (108), the glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide (95), and the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin (109), verifying its validity as a translational model.